Biotech Values

[ariadndndough]

dew this is were i got that 20 billion dollar figure

The data, reported at the American Heart Association meeting in Chicago, will revive interest in a class of medicines that may reach peak sales of $19 billion a year, said Nikhil Mehta, director of cardiovascular disorders at Decision Resources Inc., a consulting firm. Investors who lowered expectations after the failure of Pfizer’s pill torcetrapib, in a family of medicines known as CETP inhibitors, may now change their view, he said.


from bloomberg

what i am trying to say that no one gave this drug a chance after today it has pretty good chance and mrk stock price could be attractive longterm

dough